Praxis Precision Medicines (PRAX) reported a FY 2025 net loss of USD 303.3 million and a Q4 2025 net loss of USD 88.9 million, including stock-based compensation expense of USD 33.9 million for FY 2025 and USD 9.9 million for Q4 2025. R&D expenses were USD 267.1 million for FY 2025 and USD 77.5 million for Q4 2025, while G&A expenses were USD 59.1 million for FY 2025 and USD 19.5 million for Q4 2025. Cash, cash equivalents and marketable securities totaled USD 926.1 million as of Dec. 31, 2025, and the company also reported net proceeds of USD 621.2 million from a January 2026 follow-on public offering, which it said are expected to fund operations into 2028. Shares outstanding were 25.2 million as of Dec. 31, 2025. On the business front, Praxis said it submitted two NDAs to the FDA: ulixacaltamide for essential tremor following a positive pre-NDA meeting in December 2025, and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies based on efficacy in the EMBOLD registrational cohort. The company said pre-launch activities for both programs are underway and expected to accelerate through 2026, and it plans to present Essential3 results for ulixacaltamide at the American Academy of Neurology meeting in April 2026. Praxis also reiterated upcoming clinical milestones, including POWER1 Phase 3 topline results for vormatrigine in focal onset seizures expected in Q2 2026 and EMBRAVE Part A topline results for elsunersen expected in H1 2026, and announced January 2026 board and leadership updates including the appointments of Jeffrey B. Kindler and Stuart Arbuckle to its board and Orrin Devinsky as Head of Clinical Strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9657233-en) on February 19, 2026, and is solely responsible for the information contained therein.